- Home
- PPBT vs TTNP Comparison
PPBT vs TTNP Comparison
Compare PPBT & TTNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- TTNP
- Stock Information
- Founded
- PPBT 2010
- TTNP 1991
- Country
- PPBT Israel
- TTNP United States
- Employees
- PPBT N/A
- TTNP 4
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPBT Health Care
- TTNP Health Care
- Exchange
- PPBT Nasdaq
- TTNP Nasdaq
- Market Cap
- PPBT 6.3M
- TTNP 5.9M
- IPO Year
- PPBT N/A
- TTNP 1996
- Fundamental
- Price
- PPBT $2.34
- TTNP $4.40
- Analyst Decision
- PPBT Strong Buy
- TTNP
- Analyst Count
- PPBT 1
- TTNP 0
- Target Price
- PPBT $33.00
- TTNP N/A
- AVG Volume (30 Days)
- PPBT 29.4K
- TTNP 44.6K
- Earning Date
- PPBT 08-15-2025
- TTNP 08-14-2025
- Dividend Yield
- PPBT N/A
- TTNP N/A
- EPS Growth
- PPBT N/A
- TTNP N/A
- EPS
- PPBT N/A
- TTNP N/A
- Revenue
- PPBT N/A
- TTNP N/A
- Revenue This Year
- PPBT N/A
- TTNP N/A
- Revenue Next Year
- PPBT N/A
- TTNP N/A
- P/E Ratio
- PPBT N/A
- TTNP N/A
- Revenue Growth
- PPBT N/A
- TTNP N/A
- 52 Week Low
- PPBT $2.00
- TTNP $3.03
- 52 Week High
- PPBT $13.95
- TTNP $14.80
- Technical
- Relative Strength Index (RSI)
- PPBT 41.27
- TTNP 48.35
- Support Level
- PPBT $2.30
- TTNP $4.23
- Resistance Level
- PPBT $2.45
- TTNP $4.65
- Average True Range (ATR)
- PPBT 0.14
- TTNP 0.27
- MACD
- PPBT -0.03
- TTNP -0.03
- Stochastic Oscillator
- PPBT 16.58
- TTNP 30.67
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.